Vividion Therapeutics
Vividion Therapeutics is a biopharmaceutical company dedicated to transforming patient care by developing small molecule therapeutics targeting traditionally undruggable proteins involved in cancers and immune disorders. Leveraging its proprietary chemoproteomic platform, Vividion identifies novel binding pockets on protein targets and develops highly selective small molecule drugs. As a wholly owned subsidiary of Bayer AG, Vividion operates with an entrepreneurial culture, advancing a diversified pipeline of first-in-class medicines in oncology and immunology.
Industries
Nr. of Employees
large (251-1000)
Vividion Therapeutics
Patents
Products
WRN inhibitor (clinical-stage)
A clinical-stage small-molecule inhibitor program targeting WRN for oncology indications; advancing in development as reported in company communications.
RAS–PI3Kα covalent inhibitor (Phase I)
A covalent small-molecule inhibitor designed to block the RAS–PI3Kα interaction; advanced to a Phase I study with first patient dosing reported.
KEAP1 activator program (preclinical candidate VVD-065)
A preclinical program developing small-molecule activators of KEAP1 with an identified candidate reported in scientific posters and company communications.
Pipeline of selective small-molecule programs against undruggable targets
A diversified pipeline of first-in-class and early-stage small-molecule programs in oncology and immunology enabled by chemoproteomics and covalent chemistry.
VVD-037
A highly selective, first-in-class small molecule activator of KEAP1 that allosterically enhances the ability of this E3 ligase to degrade its natural cellular target, NRF2, to inhibit tumor growth in NRF2-hyperactivated solid tumors.
VVD-642
A small molecule RAS-PIK3CA inhibitor that specifically blocks the interaction between RAS and PIK3CA to inhibit oncogenic signaling without disrupting homeostatic signaling.
WRN inhibitor (clinical-stage)
A clinical-stage small-molecule inhibitor program targeting WRN for oncology indications; advancing in development as reported in company communications.
RAS–PI3Kα covalent inhibitor (Phase I)
A covalent small-molecule inhibitor designed to block the RAS–PI3Kα interaction; advanced to a Phase I study with first patient dosing reported.
KEAP1 activator program (preclinical candidate VVD-065)
A preclinical program developing small-molecule activators of KEAP1 with an identified candidate reported in scientific posters and company communications.
Pipeline of selective small-molecule programs against undruggable targets
A diversified pipeline of first-in-class and early-stage small-molecule programs in oncology and immunology enabled by chemoproteomics and covalent chemistry.
VVD-037
A highly selective, first-in-class small molecule activator of KEAP1 that allosterically enhances the ability of this E3 ligase to degrade its natural cellular target, NRF2, to inhibit tumor growth in NRF2-hyperactivated solid tumors.
VVD-642
A small molecule RAS-PIK3CA inhibitor that specifically blocks the interaction between RAS and PIK3CA to inhibit oncogenic signaling without disrupting homeostatic signaling.
Services
Partnership-based collaborations to discover, validate, and position oncology targets and associated biomarkers using chemoproteomics and functional genomics.
Integrated discovery capabilities combining chemoproteomic screening, a covalent chemistry library, and data integration to generate selective small-molecule starting points against challenging targets.
Partnership-based collaborations to discover, validate, and position oncology targets and associated biomarkers using chemoproteomics and functional genomics.
Integrated discovery capabilities combining chemoproteomic screening, a covalent chemistry library, and data integration to generate selective small-molecule starting points against challenging targets.
Expertise Areas
- Chemoproteomics-driven drug discovery
- Covalent small-molecule discovery and optimization
- Target identification and validation for undruggable proteins
- Functional and computational genomics for oncology target discovery
Key Technologies
- Chemoproteomics
- Proteome-wide covalent ligand screening
- Covalent fragment-based ligand discovery
- Proteome-trained covalent chemistry library